Axiom signs deal with medical company to do diabetes monitor research on its next manned mission to ISSAxiom today announced it has signed a deal with the medical company Burjeel Holdings to fly and test a glucose monitor during its May 2025 AX-4 manned mission to ISS.
The Ax-4 mission will utilize Continuous Glucose Monitors (CGMs), which have become the standard for glucose monitoring in individuals with diabetes. These devices will be tested to ensure their accuracy in microgravity, providing real-time data that will ultimately support the health of astronauts with insulin-dependent diabetes.The comprehensive preflight, inflight, and post flight protocols will employ various testing methods to validate these technologies. The Ax-4 mission also plans to look at insulin exposure in microgravity to assess the potency and stability of the drug product upon its return to Earth.
Testing the behavior of CGMs and insulin delivery technologies in microgravity and with circadian rhythm disruption is expected to advance the understanding of how such innovations can improve diabetes monitoring and care in remote or under served areas on Earth. Experts say this research will lay the groundwork for managing diabetes in isolated locations, such as oil rigs, deserts, or rural regions.
These tests will also make it possible for people who have diabetes to go into space. For Axiom, this will help widen its customer base. For Burjeel it proves its monitors can work in many remote and hostile environments, also widening its customer base.
Hat tip BtB’s stringer Jay, who adds that “This is cool since this is two companies and no NASA/government involvement.”
On Christmas Eve 1968 three Americans became the first humans to visit another world. What they did to celebrate was unexpected and profound, and will be remembered throughout all human history. Genesis: the Story of Apollo 8, Robert Zimmerman's classic history of humanity's first journey to another world, tells that story, and it is now available as both an ebook and an audiobook, both with a foreword by Valerie Anders and a new introduction by Robert Zimmerman.
The print edition can be purchased at Amazon. from any other book seller, or direct from my ebook publisher, ebookit.
The ebook is available everywhere for $5.99 (before discount) at amazon, or direct from my ebook publisher, ebookit. If you buy it from ebookit you don't support the big tech companies and the author gets a bigger cut much sooner.
The audiobook is also available at all these vendors, and is also free with a 30-day trial membership to Audible.
"Not simply about one mission, [Genesis] is also the history of America's quest for the moon... Zimmerman has done a masterful job of tying disparate events together into a solid account of one of America's greatest human triumphs."--San Antonio Express-News
Axiom today announced it has signed a deal with the medical company Burjeel Holdings to fly and test a glucose monitor during its May 2025 AX-4 manned mission to ISS.
The Ax-4 mission will utilize Continuous Glucose Monitors (CGMs), which have become the standard for glucose monitoring in individuals with diabetes. These devices will be tested to ensure their accuracy in microgravity, providing real-time data that will ultimately support the health of astronauts with insulin-dependent diabetes.The comprehensive preflight, inflight, and post flight protocols will employ various testing methods to validate these technologies. The Ax-4 mission also plans to look at insulin exposure in microgravity to assess the potency and stability of the drug product upon its return to Earth.
Testing the behavior of CGMs and insulin delivery technologies in microgravity and with circadian rhythm disruption is expected to advance the understanding of how such innovations can improve diabetes monitoring and care in remote or under served areas on Earth. Experts say this research will lay the groundwork for managing diabetes in isolated locations, such as oil rigs, deserts, or rural regions.
These tests will also make it possible for people who have diabetes to go into space. For Axiom, this will help widen its customer base. For Burjeel it proves its monitors can work in many remote and hostile environments, also widening its customer base.
Hat tip BtB’s stringer Jay, who adds that “This is cool since this is two companies and no NASA/government involvement.”
On Christmas Eve 1968 three Americans became the first humans to visit another world. What they did to celebrate was unexpected and profound, and will be remembered throughout all human history. Genesis: the Story of Apollo 8, Robert Zimmerman's classic history of humanity's first journey to another world, tells that story, and it is now available as both an ebook and an audiobook, both with a foreword by Valerie Anders and a new introduction by Robert Zimmerman.
The print edition can be purchased at Amazon. from any other book seller, or direct from my ebook publisher, ebookit. The ebook is available everywhere for $5.99 (before discount) at amazon, or direct from my ebook publisher, ebookit. If you buy it from ebookit you don't support the big tech companies and the author gets a bigger cut much sooner.
The audiobook is also available at all these vendors, and is also free with a 30-day trial membership to Audible.
"Not simply about one mission, [Genesis] is also the history of America's quest for the moon... Zimmerman has done a masterful job of tying disparate events together into a solid account of one of America's greatest human triumphs."--San Antonio Express-News
Readers: the rules for commenting!
No registration is required. I welcome all opinions, even those that strongly criticize my commentary.
However, name-calling and obscenities will not be tolerated. First time offenders who are new to the site will be warned. Second time offenders or first time offenders who have been here awhile will be suspended for a week. After that, I will ban you. Period.
Note also that first time commenters as well as any comment with more than one link will be placed in moderation for my approval. Be patient, I will get to it.